# EDGAR Filing Document

**Accession Number:** 0001781983
**File Stem:** 0001104659-26-049298
**Filing Date:** 2026-4
**Character Count:** 2360
**Document Hash:** 6d8e0f58394d2d50ce1246992ceb665f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-049298.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001104659-26-049298

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aprea Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902
- **BUSINESS PHONE:** 215-948-4119

**MAIL ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902

**APREA THERAPEUTICS, INC.**

**3805 Old Easton Road**

**Doylestown, PA 18902**

April 27, 2026

**VIA EDGAR**

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Doris Stacey Gama

---

| | |
|:---|:---|
| Re: | Aprea Therapeutics, Inc. |
|  | Registration Statement on Form S-3 |
|  | File No. 333-295247 |
|  | Request for Acceleration |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the "**Registrant**") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295247), so that it may become effective at 5:00 p.m. Eastern Time on April 29, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **APREA THERAPEUTICS, INC.** | **APREA THERAPEUTICS, INC.** |
| By: | /s/ Oren Gilad |
| Name: | Oren Gilad |
| Title: | Chief Executive Officer |

---

cc: Fahd Riaz, Esq., *DLA Piper LLP (US)* <br> Dylan Caplan, Esq., *DLA Piper LLP (US)*